Encora Therapeutics
Category: AI in Healthcare
A non-invasive wearable wristband that uses AI-powered vibration therapy to counteract hand tremors for people with Essential Tremor. Encora Therapeutics was founded in 2018. The company is led by Nadim Yared. Based in Cambridge, Massachusetts, USA. Team size: 1-10. Total funding raised: $1.5M. Latest round: Grant, $20K, 2021-12. Key investors include Innospark Ventures, Good Growth Capital, Creative Destruction Lab, Ignite Medtech, gener8tor, The Engine.
- Founded
- 2018
- Headquarters
- Cambridge, Massachusetts, USA
- Team size
- 1-10
- Total funding
- $1.5M
Value proposition
Offers a non-invasive, drug-free wearable solution that uses real-time AI and personalized vibration feedback to stabilize a user's hand, improving their ability to perform daily activities.
Products and solutions
Encora X1: FDA-cleared non-invasive wearable wristband that uses proprietary AI algorithms to deliver personalized mechanical stimulation for on-demand tremor relief., Companion Mobile App: Allows for device configuration, data tracking, and reporting for users and clinicians.
Unique value
Encora Therapeutics's core innovation is its use of proprietary, on-device AI algorithms that provide real-time, adaptive vibrotactile (vibration) therapy. The system actively senses and then cancels out tremor motions through precisely timed haptic feedback.
Target customer
Individuals with Essential Tremor, as well as healthcare providers, neurologists, and movement disorder specialists.
Industries served
Healthcare, MedTech, Digital Therapeutics, Wearable Technology
Technology advantage
The primary advantage is the on-device (edge AI) processing, which allows for immediate tremor response without latency. Its approach is non-invasive and non-pharmaceutical, offering an alternative to drugs or surgery like deep brain stimulation.
How they differentiate
Encora differentiates itself by using AI-driven haptic (vibratory) feedback rather than electrical stimulation (Cala) or mechanical gyroscopes (GyroGear). Its system is designed to be highly adaptive and responsive in real-time to the user's specific tremor patterns.
Main competitors
Cala Health, GyroGear, Allevion Therapeutics, Steadiwear, five microns
Key partnerships
The Engine (Venture firm built by MIT), HTD Health (for mobile application development), gBETA MedTech Accelerator, Harvard-MIT Health Sciences and Technology
Notable customers
Clinical trial participants. FDA clearance received Feb 2026; commercial launch underway.
Major milestones
Founded as an MIT spin-off., Participation in the Creative Destruction Lab and gBETA MedTech accelerator programs., Successfully completed the multi-center ULTRE clinical trial., Received 'Abstract of Distinction' at the 2025 American Academy of Neurology (AAN) Annual Meeting for its clinical trial results., Received FDA 510(k) clearance for Encora X1 wearable device (February 2026).
Growth metrics
Successfully completed the ULTRE clinical trial in late 2024. Received FDA 510(k) clearance for Encora X1 in February 2026, enabling commercial launch.
Market positioning
A commercial-stage, venture-backed medtech company with FDA 510(k) clearance, targeting the non-invasive neuromodulation market for movement disorders with an AI-driven wearable.
Geographic focus
Initially focused on the United States market.
Patents and IP
The company has pending patents related to its proprietary vibratory stimulation technology and closed-loop sensor-actuator system for active tremor cancellation.
About Nadim Yared
President & CEO, CVRx (led company through IPO in 2021); more than two decades of medtech leadership experience
Official website: https://encoratherapeutics.com/